Antonio Paul on Blame Game in Transplantation: HLA vs Microbes
Antonio Paul, Head of ACTIMoS- Advanced Center for Transplant Immunology and Molecular Science, shared on LinkedIn:
”Blame Game in Transplantation: HLA vs Microbes
What if HLA antibodies are not always about HLA?
For decades, we’ve taught that anti-HLA antibodies arise from the usual suspects:
- Prior transplants
- Blood transfusions
- Pregnancy
But many patients develop de novo anti-HLA antibodies without any classic sensitization history.
Growing evidence suggests another culprit: Infections.
What’s happening?
Microbes can trigger HLA antibodies through several mechanisms:
- Molecular mimicry – Microbial antigens may resemble HLA epitopes, leading to cross-reactive antibodies.
- Innate immune “danger signals” – Toll-like receptor activation can break immune tolerance and promote rejection.
- Bystander B-cell activation – Cytokine surges during infection can awaken dormant HLA-reactive memory B cells.
- Polyclonal immune activation – Broad antibody expansion may occur after infections or vaccinations.
Clinical evidence shows that infections often precede:
– Increased panel reactive antibodies (PRA)
– Emergence of donor-specific antibodies (DSA)
– Higher rejection risk
– Poorer graft survival
Rethinking an old assumption
Not all HLA antibodies are born from mismatched HLA.
Some may be born from mismatched microbes.
Transplant success may depend not only on how well donors and recipients are matched, but also on which microbes the immune system remembers.”

Stay updated with Hemostasis Today.
-
Jan 22, 2026, 15:36We Must Roll Up Our Sleeves And Help: José Antonio García Erce on Plasma Donation
-
Jan 22, 2026, 15:25Nita Radhakrishnan on Challenges In Congenital Afibrinogenemia
-
Jan 22, 2026, 15:10Jin Q Gives a Summary of 2025’s Most Impactful Cell and Gene Therapy Milestones
-
Jan 22, 2026, 14:57Nirav Dhanesha on CD14 Acting As A Functional Driver of DVT
-
Jan 22, 2026, 11:41Jamilla Goedegebuur and Colleagues on VTE Management in Case of PAD
-
Jan 22, 2026, 11:28Abdulrahman Katib on API-CAT Trial’s Evaluation of Apixaban Dosing
-
Jan 22, 2026, 11:19Bruno Odisio: Ablation Margins Are Software-Dependent
-
Jan 22, 2026, 10:38Pedro Perez: The VTE Market Is Clearly Entering Its Next Phase
-
Jan 22, 2026, 10:29Marvin Garcia Reyes Presents a Case of Aorto-Visceral and Aorto-Iliac Thrombosis
